Positive results from the Phase 2 study RILECSU showed that rilzabrutinib significantly improved itch, hives and urticaria in adults with moderate-to-severe chronic spontaneous urticaria (CSU), whose symptoms are not adequately controlled by H1 antihistamines. These results were released at the 2024 American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting and form the basis for the Phase 3 program which is on track to start in 2024. Rilzabrutinib is an oral, reversible, covalent BTK inhibitor that has the potential to be a first- or best-in-class treatment of a number of immune-mediated diseases. Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.
Buscar 
+86 21 5895 0110 
